Hematologic Oncology

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

New data demonstrate that older adolescents with acute lymphoblastic leukemia (ALL) can be cured using risk-adjusted intensive chemotherapy without prophylactic cranial irradiation or routine stem cell transplantation.

The aggressive peripheral T-cell lymphomas make up less than 10% of all lymphomas diagnosed each year in the United States.

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

Useful Online Resources and Clinical Trials for Non-Hodgkin Lymphoma

Useful Online Resources and Clinical Trials for Acute Myelogenous Leukemia

Imatinib (Gleevec) improves the ability to proceed with allogeneic stem cell transplantation and improves 5-year overall survival (OS) when used as induction therapy in patients with Philadelphia chromosome positive (Ph ) acute lymphoblastic leukemia

A new scoring system has been developed that is designed to predict the risk of recurrent venous thromboembolism (VTE) in a patient with cancer.

An investigational pan-BCR-ABL inhibitor designed to inhibit the entire spectrum of mutations responsible for resistance to drugs such as imatinib (Gleevec) and its cousins nilotinib (Tasigna) and dasatinib (Sprycel) appears to fulfill its promise.

In patients with early unfavorable Hodgkin lymphoma, an escalated BEACOPP regimen was superior to standard treatment at improving tumor control, according to final data from the German Hodgkin Study Group HD14 trial.

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

The novel first-in-class agent CPX-351 liposome injection improved response rates and eventfree survival in elderly patients with newly diagnosed acute myeloid leukemia.

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.

Intensified immunochemotherapy with R-ACVBP significantly improved event-free survival, progression-free survival, disease-free survival, and overall survival compared with R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL), but at the cost of increased hematologic toxicity.

About 13,300 new cases of acute myeloid leukemia (AML) are diagnosed yearly, and nearly 9,000 deaths occur in the United States.

Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.

An investigational drug known as brentuximab vedotin (SGN-35) achieved dramatic responses in a pivotal phase II study involving younger patients with relapsed or refractory Hodgkin lymphoma.

Bosutinib (SKI-606) seems poised to join the tyrosine kinase inhibitors (TKIs) imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) as a first-line therapy option for patients with chronic myelogenous leukemia in the chronic phase.